Navigation Links
Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Date:6/1/2011

NEW YORK, June 1, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017

http://www.reportlinker.com/p0546797/Osteosarcoma-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, "Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global Osteosarcoma Therapeutics market. The report identifies the key trends shaping and driving the global Osteosarcoma Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Osteosarcoma Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Osteosarcoma Therapeutics market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Osteosarcoma Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.

- Analysis of the current and future competition in the seven key countries Osteosarcoma Therapeutics market.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Osteosarcoma Therapeutics therapeutics market.

- Analysis of key recent licensing and partnership agreements in Osteosarcoma Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Osteosarcoma Therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Osteosarcoma Therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global Osteosarcoma Therapeutics market landscape? – Identify, understand and capitalize.

1 Table of contents

1 Table of contents 3

1.1 List of Tables 5

1.2 List of Figures 6

2 Osteosarcoma Therapeutics: Introduction 7

2.1 Overview 7

2.2 Epidemiology 8

2.3 Etiology 8

2.4 Symptoms 9

2.5 Staging of Osteosarcoma 9

2.5.1 American Joint Committee on Cancer (AJCC) Staging System 9

2.6 Diagnosis of Osteosarcoma 12

2.6.1 Imaging Techniques 12

2.6.2 Biopsy 15

2.6.3 Blood Tests 15

2.7 Treatment Options by Stage 15

2.7.1 Localized Osteosarcoma 15

2.7.2 Metastatic Osteosarcoma 15

2.7.3 Recurrent Osteosarcoma 15

2.8 Treatment and Management pattern of Osteosarcoma 15

2.8.1 Surgery 15

2.8.2 Radiation Therapy 16

2.8.3 Chemotherapy 16

2.9 GlobalData Pipeline Report Guidance 17

3 Osteosarcoma Therapeutics: Market Characterization 18

3.1 Osteosarcoma Therapeutics Market Size, Global, 2005-2010 18

3.2 Osteosarcoma Therapeutics Market Forecast, Global, 2010-2017 19

3.3 Osteosarcoma Therapeutics Market Size, The US, 2005-2010 20

3.4 Osteosarcoma Therapeutics Market Forecast, The US, 2010-2017 21

3.5 Osteosarcoma Therapeutics Market Size, France, 2005-2010 22

3.6 Osteosarcoma Therapeutics Market Forecast, France, 2010-2017 23

3.7 Osteosarcoma Therapeutics Market Size, Germany 2005-2010 24

3.8 Osteosarcoma Therapeutics Market Forecast, Germany, 2010-2017 25

3.9 Osteosarcoma Therapeutics Market Size, Italy, 2005-2010 26

3.10 Osteosarcoma Therapeutics Market Forecast, Italy, 2010-2017 27

3.11 Osteosarcoma Therapeutics Market Size, Spain, 2005-2010 28

3.12 Osteosarcoma Therapeutics Market Forecast, Spain, 2010-2017 29

3.13 Osteosarcoma Therapeutics Market Size, The UK, 2005-2010 30

3.14 Osteosarcoma Therapeutics Market Forecast, The UK, 2010-2017 31

3.15 Osteosarcoma Therapeutics Market Size, Japan, 2005-2010 32

3.16 Osteosarcoma Therapeutics Market Forecast, Japan, 2010-2017 33

3.17 Drivers and Barriers for the Osteosarcoma Therapeutics Market 34

3.17.1 Drivers for the Osteosarcoma Therapeutics Market 34

3.17.2 Barriers for the Osteosarcoma Therapeutics Market 34

3.18 Opportunity and Unmet Need Analysis 35

3.19 Key Takeaway 35

4 Osteosarcoma Therapeutics: Competitive Assessment 36

4.1 Overview 36

4.1.1 Strategic Competitor Assessment 36

4.2 Major Marketed Product Profiles in the Osteosarcoma Therapeutics Market 37

4.2.1 Drugs Influencing Structure and Function of Deoxyribonucleic Acid (DNA) 37

4.2.2 Drugs Inhibiting Biosynthesis of Nucleic Acids 38

4.2.3 Drugs Interfering with Microtubule Assembly 39

4.3 Key Takeaway 39

5 Osteosarcoma Therapeutics: Pipeline Assessment 40

5.1 Overview 40

5.2 Strategic Pipeline Assessment 40

5.3 Osteosarcoma Therapeutics Pipeline, Pipeline by Phases of Development 41

5.3.1 Osteosarcoma Therapeutics, Phase III Pipeline, 2011 41

5.3.2 Osteosarcoma Therapeutics, Phase II Pipeline, 2011 41

5.3.3 Osteosarcoma Therapeutics, Phase I Pipeline, 2011 42

5.3.4 Osteosarcoma Therapeutics, Preclinical Pipeline, 2011 42

5.4 Osteosarcoma Therapeutics, Pipeline by Mechanism of Action 43

5.5 Technology Trends Analytic Framework 44

5.6 Osteosarcoma Therapeutics Pipeline by Monotherapy and Combination Therapy 46

5.7 Osteosarcoma Therapeutics, Promising Drugs Under Clinical Development 47

5.8 Molecule Profile for Promising Drugs Under Clinical Development 48

5.8.1 Ridaforolimus (MK8669, AP23573, Deforolimus) 48

5.8.2 Mepact (mifamurtide) 49

5.8.3 Rexin-G 49

5.9 Key Takeaway 50

6 Osteosarcoma Therapeutics: Clinical Trials Mapping 51

6.1 Clinical Trials by Country (US, EU5 and Japan) 51

6.2 Clinical Trials by Phase 52

6.3 Clinical Trials by Trial Status 53

6.4 Prominent Sponsors 54

6.5 Top Companies Participating in Osteosarcoma Therapeutics Clinical Trials 56

7 Osteosarcoma Therapeutics: Strategic Assessment 57

7.1 Key Events Impacting the Future Market 57

7.2 Osteosarcoma Therapeutics: Implications for Future Market Competition 58

8 Osteosarcoma Therapeutics: Future Players 59

8.1 Introduction 59

8.2 Company Profiles 60

8.2.1 Millennium Pharmaceuticals, Inc. 60

8.2.2 Merck & Co 62

8.2.3 ZIOPHARM Oncology, Inc 68

8.2.4 Oncolytics Biotech Inc. 70

8.2.5 Epeius Biotechnologies Corporation 72

8.2.6 Hawthorn Pharmaceuticals, Inc. 73

8.2.7 Other Companies in the Osteosarcoma Therapeutics Market 74

9 Osteosarcoma Therapeutics: Licensing and Partnership Deals 75

10 Osteosarcoma Therapeutics: Appendix 76

10.1 Market Definitions 76

10.2 Abbreviations 76

10.3 Methodology 77

10.3.1 Coverage 77

10.3.2 Secondary Research 77

10.3.3 Forecasting 78

10.3.4 Primary Research 81

10.3.5 Expert Panel Validation 81

10.4 Contact Us 81

10.5 Disclaimer 81

10.6 Bibliography 82

1.1 List of Tables

Table 1: Histological Classification of Osteosarcoma - WHO 8

Table 2: Osteosarcoma Therapeutics Market, Global, Revenue ($m), 2005–2010 18

Table 3: Osteosarcoma Therapeutics Market, Global, Forecast ($m), 2010–2017 19

Table 4: Osteosarcoma Therapeutics Market, The US, Revenue ($m), 2005–2010 20

Table 5: Osteosarcoma Therapeutics Market, The US, Forecast ($m), 2010–2017 21

Table 6: Osteosarcoma Therapeutics Market, France, Revenue ($m), 2005–2010 22

Table 7: Osteosarcoma Therapeutics Market, France, Forecast ($m), 2010–2017 23

Table 8: Osteosarcoma Therapeutics Market, Germany, Revenue ($m), 2005–2010 24

Table 9: Osteosarcoma Therapeutics Market, Germany, Forecast ($m), 2010–2017 25

Table 10: Osteosarcoma Therapeutics Market, Italy, Revenue ($m), 2005–2010 26

Table 11: Osteosarcoma Therapeutics Market, Italy, Forecast ($m), 2010–2017 27

Table 12: Osteosarcoma Therapeutics Market, Spain, Revenue ($m), 2005–2010 28

Table 13: Osteosarcoma Therapeutics Market, Spain, Forecast ($m), 2010–2017 29

Table 14: Osteosarcoma Therapeutics Market, The UK, Revenue ($m), 2005–2010 30

Table 15: Osteosarcoma Therapeutics Market, The UK, Forecasts ($m), 2010–2017 31

Table 16: Osteosarcoma Therapeutics Market, Japan, Revenue ($m), 2005–2010 32

Table 17: Osteosarcoma Therapeutics Market, Japan, Forecasts ($m), 2010–2017 33

Table 18: Adjuvant Chemotherapy for Osteosarcoma with Methotrexate Combination 38

Table 19: Osteosarcoma Therapeutics, Phase III Pipeline, 2011 41

Table 20: Osteosarcoma Therapeutics, Phase II Pipeline, 2011 41

Table 21: Osteosarcoma Therapeutics, Phase I Pipeline, 2011 42

Table 22: Osteosarcoma Therapeutics, Preclinical Pipeline, 2011 42

Table 23: Osteosarcoma Therapeutics – Most Promising Drugs Under Clinical Development, 2011 47

Table 24: Rexin-G, Summary of Phase II Trial Results, 2010 50

Table 25: Osteosarcoma Therapeutics, Clinical Trials by Country, 2011 51

Table 26: Osteosarcoma Therapeutics, Clinical Trials by Phase, 2011 52

Table 27: Osteosarcoma Therapeutics, Clinical Trials by Status, 2011 53

Table 28: Osteosarcoma Therapeutics, Prominent Sponsors, 2011 55

Table 29: Osteosarcoma Therapeutics, Top Companies Participating in Osteosarcoma Therapeutics Clinical Trials, 2011 56

Table 30: Millennium Pharmaceuticals, Inc.– Oncology Pipeline, 2011 61

Table 31: Millennium Pharmaceuticals, Inc – Molecules in Pipeline for Osteosarcoma, 2011 61

Table 32: Millennium Pharmaceuticals, Inc – Deals 62

Table 33: Merck & Co Oncology Inc – Oncology Pipeline, 2011 64

Table 34: Merck & Co – Molecules in Pipeline for Osteosarcoma, 2011 65

Table 35: Merck & Co., Inc. – Deals 66

Table 36: ZIOPHARM Oncology Inc – Oncology Pipeline, 2011 69

Table 37: ZIOPHARM Oncology Inc – Molecules in Pipeline for Osteosarcoma, 2011 69

Table 38: ZIOPHARM Oncology Inc – Deals 70

Table 39: Oncolytics Biotech Inc – Oncology Pipeline, 2011 71

Table 40: Oncolytics Biotech Molecules in Pipeline for osteosarcoma, 2011 72

Table 41: Oncolytics Biotech- Deals 72

Table 42: Epeius Biotechnologies Corporation, Pipeline, 2011 72

Table 43: Epeius Biotechnologies Corporation, Pipeline, 2011 73

Table 44: Hawthorn Pharmaceuticals,Inc. – Oncology Pipeline, 2011 73

Table 45: Hawthorn Pharmaceuticals,Inc – Osteosarcoma Pipeline, 2011 73

Table 46: Hawthorn Pharmaceuticals,Inc – Deals 74

Table 47: Osteosarcoma Therapeutics Market – Future Players 74

Table 48: Licensing and Partnership Deals 75

1.2 List of Figures

Figure 1: Major Sites of Osteosarcoma 7

Figure 2: Staging of Osteosarcoma 10

Figure 3: Staging of Osteosarcoma 11

Figure 4: Bone X-ray of Osteosarcoma Patient 12

Figure 5: CT Scan of Osteosarcoma Patient 12

Figure 6: Chest X-ray of Osteosarcoma Patient 13

Figure 7: MRI of Osteosarcoma Patient 13

Figure 8: Bone Scan of Osteosarcoma Patient 14

Figure 9: PET Scan of Osteosarcoma Patient 14

Figure 10: Osteosarcoma Therapeutics Market, Global, Revenue ($m), 2005–2010 18

Figure 11: Osteosarcoma Therapeutics Market, Global, Forecast ($m), 2010–2017 19

Figure 12: Osteosarcoma Therapeutics Market, The US, Revenue ($m), 2005–2010 20

Figure 13: Osteosarcoma Therapeutics Market, The US, Forecast ($m), 2010–2017 21

Figure 14: Osteosarcoma Therapeutics Market, France, Revenue ($m), 2005–2010 22

Figure 15: Osteosarcoma Therapeutics Market, France, Forecast ($m), 2010–2017 23

Figure 16: Osteosarcoma Therapeutics Market, Germany, Revenue ($m), 2005–2010 24

Figure 17: Osteosarcoma Therapeutics Market, Germany, Forecast ($m), 2010–2017 25

Figure 18: Osteosarcoma Therapeutics Market, Italy, Revenue ($m), 2005–2010 26

Figure 19: Osteosarcoma Therapeutics Market, Italy, Forecast ($m), 2010–2017 27

Figure 20: Osteosarcoma Therapeutics Market, Spain, Revenue ($m), 2005–2010 28

Figure 21: Osteosarcoma Therapeutics Market, Spain, Forecast ($m), 2010–2017 29

Figure 22: Osteosarcoma Therapeutics Market, The UK, Revenue ($m), 2005–2010 30

Figure 23: Osteosarcoma Therapeutics Market, The UK, Forecast ($m), 2010–2017 31

Figure 24: Osteosarcoma Therapeutics Market, Japan, Revenue ($m), 2005–2010 32

Figure 25: Osteosarcoma Therapeutics Market, Japan, Forecast ($m), 2010–2017 33

Figure 26: Opportunity and Unmet Need in the Osteosarcoma Therapeutics Market, 2010 35

Figure 27: Osteosarcoma Therapeutics, Strategic Competitor Assessment, 2011 36

Figure 28: Osteosarcoma Therapeutics, Pipeline by Phase of Development, 2011 41

Figure 29: Osteosarcoma Therapeutics, Pipeline by Mechanism of Action, 2011 43

Figure 30: Osteosarcoma Therapeutics, Technology Trends Analytics Framework, 2011 44

Figure 31: Osteosarcoma Therapeutics, Technology Trends Analytics Framework, Description, 2011 45

Figure 32: Osteosarcoma Pipeline Products by Monotherapy and Combination therapy, 2011 46

Figure 33: Osteosarcoma Therapeutics, Clinical Trials by Country, 2011 51

Figure 34: Osteosarcoma Therapeutics, Clinical Trials by Phase, 2011 52

Figure 35: Osteosarcoma Therapeutics, Clinical Trials by Status, 2011 53

Figure 36: Osteosarcoma Therapeutics, Overall Sponsors, 2011 54

Figure 37: Osteosarcoma Therapeutics, Prominent Sponsors, 2011 55

Figure 38: Osteosarcoma Therapeutics, Top Companies Participating in Osteosarcoma Therapeutics Clinical Trials, 2011 56

Figure 39: Osteosarcoma Therapeutics Market, Drivers and Restraints 2011 57

Figure 40: Implications for Future Market Competition in the Osteosarcoma Therapeutics Market, 2011 58

Figure 41: Osteosarcoma Therapeutics, Pipeline by Company, 2011 59

Figure 42: GlobalData Market Forecasting Model 80

Companies Mentioned

Millennium Pharmaceuticals, Inc.

Merck & Co

ZIOPHARM Oncology, Inc

Oncolytics Biotech Inc.

Epeius Biotechnologies Corporation

Hawthorn Pharmaceuticals, Inc.

To order this report:

Pathology Industry: Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Pathology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related biology technology :

1. Reportlinker Adds Infectious Disease Molecular Diagnostic Testing
2. Reportlinker Adds Smart Glass: Technologies and Global Markets Report
3. Reportlinker Adds Synthetic Biology: Emerging Global Markets Report
4. Reportlinker Adds Proteomics: Technologies and Global Markets Report
5. Reportlinker Adds Nanomedicine Report
6. Reportlinker Adds Small Molecule Kinase Inhibitors Report
7. Reportlinker Adds Nanoporous Materials Report
8. Reportlinker Adds Membrane Bioreactors Report
9. Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
10. Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report
11. Reportlinker Adds In Vitro Diagnostics in a Recession: IVD Market Forecasts, Analysis and Success Strategies Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... ... 20, 2016 , ... Kablooe Design, a leading provider of product design and ... anniversary of the business. “We have worked hard to build long-term relationships,” says President ... privilege and honor of serving their product design and development needs through the years.” ...
(Date:5/19/2016)... Ashland, Virginia (PRWEB) , ... May 19, 2016 , ... ... a new 30,000 square foot office building is complete. The new structure adds a ... In 2011, Anton Paar USA purchased 2.4 acres of land, along with ...
(Date:5/19/2016)... ... 19, 2016 , ... KCAS Bioanalytical and Biomarker Services, a ... Large Molecule & Biomarker Bioanalysis. , Dr. Siddiqui has more than 15 years ... preclinical and clinical safety programs. “We’ve seen significant demand for, and we are ...
(Date:5/18/2016)... ... ... Tech Coast Angels (TCA) today announced that the Angel Capital ... ACA Summit last week in Philadelphia. , The award recognizes the single-most ... It is the highest honor available for an early-stage company to receive from the ...
Breaking Biology Technology:
(Date:3/15/2016)... JERUSALEM , March 15, 2016 ... Jerusalem , the technology-transfer company of the Hebrew University, ... developer of remote sensing technology of various human biological ... funding, raising $2.0 million from private investors. ... technology, based on the detection of electromagnetic emissions from ...
(Date:3/14/2016)... Allemagne, March 14, 2016 ... - --> - Renvoi : image disponible ... --> --> DERMALOG, ... fournit de nouveaux lecteurs d,empreintes digitales pour l,enregistrement ... DERMALOG sera utilisé pour produire des cartes d,identité ...
(Date:3/11/2016)... , March 11, 2016 ... new market research report "Image Recognition Market by Technology ... (Marketing and Advertising), by Deployment Type (On-Premises and Cloud), ... To 2022", published by MarketsandMarkets, the global market is ... to USD 29.98 Billion by 2020, at a CAGR ...
Breaking Biology News(10 mins):